3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
7
Thoracic
3
Gynecologic
3
Genitourinary
3
Gastrointestinal
3
Endocrine
2
Breast
2
Other hematologic neoplasm
1
Dermatologic
1
CNS
1
Conditions
Breast Neoplasms
4
Pancreatic Neoplasms
3
Melanoma
3
Lung Neoplasms
3
Colorectal Neoplasms
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Hematologic Neoplasms
2
Glioma
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Pathologic Processes
1
Nervous System Neoplasms
1
Nervous System Diseases
1
Neoplastic Processes
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
Docetaxel
3
trastuzumab deruxtecan
1
tanespimycin
1
sargramostim
1
pertuzumab
1
pembrolizumab
1
larotrectinib
1
entrectinib
1
entinostat
1
alectinib
1
aldesleukin
1
Vorinostat
1
Trastuzumab
1
Thalidomide
1
Ritonavir
1
Radiotherapy
1
Quality of Life
1
Polymerase Chain Reaction
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Microarray Analysis
1
Indinavir
1
Immunotherapy
1
Immunohistochemistry
1
Immunoenzyme Techniques
1
Gene Expression Profiling
1
Gemcitabine
1
Flow Cytometry
1
Filgrastim
1
Fentanyl
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
Trastuzumab
×
Dermatologic
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled